In the Fourier trial, patients treated with a PCSK9 inhibitor and statin achieved LDL levels around 33 mg/dL, compared to 90-100 mg/dL in the control group.

“now remember that in the Fier trial with pcsk9 inh there was a massive decline in LDL cholesterol they got it down to 30 milligram per deciliter here the threshold that people say is magical and that cannot result in cardiovascular disease yet there still were cardiovascular disease deaths in this trial because it was a trial involving people who had had previous cardiovascular disease and even at this incredibly low level of LDL this massively miraculous finding there was no mortality benefit in this trial”

“that study was halted at something like 3.2 years but do you worry about that risk here which is you've got patients that are so heavily medicated yes you're going to exclude them if they're down at 55 but look you're going to have a lot of people at 70 milligrams per deciliter yeah but it's interesting is that we have already randomized a very robust number because we expect to be ready before the end of the year but nine thousand so you can imagine that we already have a substantial amount of people and Baseline LDL is still exactly where we want it around 100 because we have actually kind of promoted the inclusion of high LDL patients into our trial in our discussions with the sites and everything and what was another very big mistake of Fourier was that it was it was not 3.2 but it was 2.3 years”